KRAS and non-small cell lung carcinoma: KRAS accounts for 85% of RAS mutations observed in human cancer and, given that RAS is the most frequently mutated oncogene, it is the most prevalent genomic driver event in NSCLC, present in up to 35% of lung cancers [80,81].